As discussed in Note 9 to these consolidated financial statements, on May 10, 2022, our stockholders approved the LTIP, which replaced our previous stockholder-approved 2017 LTIP. The LTIP provides for the grant of a stock award either as restricted stock or as restricted stock units to officers, employees and non-employee directors. In either case, the compensation committee may determine that the award will be subject to the attainment of performance measures over an established performance period. Stock awards and the related dividend equivalents are non-transferable and subject to forfeiture if the holder does not remain continuously employed with us during the applicable restriction period or, in the case of a performance-based award, if applicable performance measures are not attained. The compensation committee will determine all of the terms relating to the satisfaction of performance measures and the termination of a restriction period, or the forfeiture and cancellation of a restricted stock award upon a termination of employment, whether by reason of disability, retirement, death or any other reason.

The agreements awarding restricted stock units under the LTIP will specify whether such awards may be settled in shares of our common stock, cash or a combination of shares and cash and whether the holder will be entitled to receive dividend equivalents, on a current or deferred basis, with respect to such award. Prior to the settlement of a restricted stock unit, the holder of a restricted stock unit will have no rights as a stockholder of the Company. The maximum number of shares available under the LTIP for restricted stock, restricted stock units and performance unit awards settled with stock (i.e., all awards other than stock options and stock appreciation rights) is 4.0 million. At December 31, 2024, 2.5 million shares were available for grant under the LTIP for such awards.

In 2024, 2023 and 2022, we granted 355,245, 396,913 and 650,355 restricted stock units, respectively, to employees under the LTIP and 2017 LTIP, with an aggregate fair value of $85.1 million, $67.0 million and $99.4 million, respectively, at the date of grant.

These 2024, 2023 and 2022 restricted stock units vest as follows: 344,600 units granted in first quarter 2024, 800 units granted in second quarter 2024, 700 units in third quarter 2024, 2,300 units in fourth quarter 2024, 390,000 units granted in first quarter 2023, and 641,000 units granted in first quarter 2022 vest in full based on continued employment through March 1, 2029, March 15, 2028 and March 15, 2027, respectively, while the other 2024, 2023 and 2022 restricted stock unit awards generally vest in full based on continued employment through the vesting period on the anniversary date of the grant. For our executive officers age 55 or older, restricted stock units awarded in 2024, 2023 and 2022 are not subject to forfeiture upon such officers’ departure from the Company after two years from the date of grant.

The vesting periods of the 2024, 2023 and 2022 restricted stock unit awards are as follows (in actual shares):


	Restricted Stock Units Granted
Vesting Period	2024		2023		2022
One year		6,800		7,360		9,270
Five years		348,445		389,553		641,085
Total shares granted		355,245		396,913		650,355

We account for restricted stock awards at historical cost, which equals its fair market value at the date of grant, which is amortized to compensation expense ratably over the vesting period of the participants. Future changes in the fair market value of our common stock that is owed to the participants do not have any impact on the amounts recorded in our consolidated financial statements. During 2024, 2023 and 2022, we charged $53.8 million, $43.4 million and $36.4 million, respectively, to compensation expense related to restricted stock awards granted in 2017 through 2023. The total intrinsic value of unvested restricted stock at December 31, 2024 and 2023 was $548.9 million and $468.5 million, respectively. During 2024 and 2023, equity awards (including accrued dividends) with an aggregate fair value of $93.5 million and $62.2 million were vested and distributed to employees under this plan.

On March 1, 2024, March 15, 2023 and March 15, 2022, pursuant to the LTIP, the compensation committee approved 58,000, 58,000 and 54,000, respectively of provisional performance share awards, with an aggregate fair value of $14.2 million, $10.3 million and $8.6 million, respectively, for future grants to our officers. Each performance share award was equivalent to the value of one share of our common stock on the date such provisional award was approved. At the end of the performance period, eligible participants will receive a number of earned shares based on the growth in adjusted EBITDAC per share (as defined in our 2024 Proxy Statement). Earned shares for the 2024, 2023 and 2022 provisional awards will fully vest based on continuous employment through March 1, 2027, March 15, 2026 and March 15, 2025, respectively, and will be settled in unrestricted shares of our common stock on a one‑for‑one basis as soon as practicable thereafter. The 2024, 2023 and 2022 awards are subject to a three-year performance period that began on January 1, 2024, 2023 and 2022, respectively, and vest on the three-year anniversary of the date of grant (March 1, 2027, March 15, 2026 and March 15, 2025). Performance share awards granted in 2023 and 2022 to certain executive officers age 55 or older, are not subject to forfeiture upon such officers’ departure from the Company after two years from the date of grant. Performance share awards granted in 2024 to executive officers are not subject to forfeiture upon such officers’ departure from the Company once they attain the age of 62. In each case, the awards vest on a pro rata basis based on the number of months rounded up during which the officer was employed during the three-year performance period. During 2024, 2023 and 2022, we recognized $22.0 million, $20.0 million and $15.2 million, respectively, to compensation expense related to performance share awards granted in 2020 through 2024. The total intrinsic value of unvested performance share awards at December 31, 2024 and 2023 was $93.0 million and $75.2 million. During 2024, 2023 and 2022, equity awards (including accrued dividends) with an aggregate fair value of $31.6 million, $28.9 million and $21.8 million were vested and distributed to employees under this plan.

Pursuant to our Performance Unit Program (which we refer to as the Program), there were no units granted in 2024 and 2023. The Program consists of a one-year performance period based on our financial performance and a three-year vesting period measured from January 1 of the year of grant. At the discretion of the compensation committee and determined based on our performance, the eligible officer or key employee will be granted a percentage of the provisional cash award units that equates to the EBITDAC growth achieved (as defined in the Program). At the end of the performance period, eligible participants will be granted a number of units based on achievement of the performance goal and subject to approval by the compensation committee. Granted units will fully vest based on continuous employment through the three-year vesting period. The ultimate award value will be equal to the trailing twelve‑month price of our common stock, multiplied by the number of units subject to the award, but limited to between 0.5 and 1.5 times the original value of the units determined as of the grant date. The fair value of the awarded units will be paid out in cash as soon as practicable. If an eligible employee leaves us prior to the vesting date, the entire award will be forfeited.

On March 15, 2022, pursuant to the Program, the compensation committee approved provisional cash awards of $19.9 million in the aggregate for future grants to our officers and key employees that are denominated in units (125,000 units in the aggregate), each of which was equivalent to the value of one share of our common stock on the date the provisional award was approved. Based on our performance for 2022, we granted 122,000 units under the Program in first quarter of 2023 that fully vested on

January 1, 2025. During 2024 and 2023 we charged $13.2 million and $13.4 million to compensation expense related to these awards. We did not recognize any compensation expense during 2022 related to the 2022 provisional award under the Program.

On March 16, 2021, pursuant to the Program, the compensation committee approved provisional cash awards of $18.8 million in the aggregate for future grants to our officers and key employees that are denominated in units (147,000 units in the aggregate), each of which was equivalent to the value of one share of our common stock on the date the provisional award was approved. Based on our performance for 2021, we granted 143,000 units under the Program in the first quarter of 2022 that fully vested on January 1, 2024. During 2023 and 2022 we charged $13.1 million and $12.4 million, respectively, to compensation expense related to these awards. We did not recognize any compensation expense during 2021 related to the 2021 provisional award under the Program.

During 2024, cash awards related to the 2021 provisional awards with an aggregate fair value of $25.4 million (129,000 units in the aggregate) were vested and distributed to employees under the Program. During 2023, cash awards related to the 2020 provisional awards with an aggregate fair value of $24.7 million (191,000 units in the aggregate) were vested and distributed to employees under the Program. During 2022, cash awards related to the 2019 provisional awards with an aggregate fair value of $21.1 million (177,000 units in the aggregate) were vested and distributed to employees under the Program.